Clinical Study
EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a
Table 3
Results of multivariable analyses: unique associations of EDSS score increase of ≥1 point with follow-up MSQOL-54 PCS and MCS.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant associations between EDSS change ≥1 point and follow-up MSQOL-54 PCS or MCS are highlighted in bold. The generalized linear model procedure was used. All models included age, sex, highest level of education (not greater than or greater than secondary), whether naïve to DMD at study onset, whether terminated the study early, and baseline HRQoL measure score. Baseline HRQoL measure score was significant in all models. DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; HRQoL, health-related quality of life; MCS, mental health composite score; MSQOL-54, Multiple Sclerosis Quality of Life-54; NS, not statistically significant; PCS, physical health composite score; SE, standard error. |